

A Review on Lquisolid Compact Technique

Dhaval Rathva, Dr.Chainesh Shah, Dr.Umesh Upadhyay

Sigma Institute Of Pharmacy, Bakrol, Vadodara-390019

Submitted: 20-04-2024

Accepted: 30-04-2024

ABSTRACT

Liquisolid strategy is an original methodology that is utilized for the upgrade of bioavailability and dissolvability of ineffectively waterinsoluble drugs. As indicated by Biopharmaceutical Order Framework (BCS), drugs are characterized in view of their solubility and permeability. The Liquisolid process is a novel and compelling way to deal with further developing dissolvability. Bioavailability depends on drug solvency. With the development of present day drug items, solvency is a major issue for the drug business. This strategy includes a planning where the fluid medication present as an answer or suspension is changed into a non tacky, dry, compactable, free-streaming powders, this is achieved by adding specific covering specialists and transporters that are fitting. This procedure with correlation with traditional tablets has the ability of improving the retention of less dissolvable medications in its atomically scattered structure, pace of disintegration, fluid dissolvability subsequently expanding its profile accessibility by utilizing less creation costs and less difficult assembling processes.

Keywords : Lquisolid, Bioavailability

I. INTRODUCTION^[1-4]

Liquisolid innovation is a promising new technique that can modify the disintegration pace of medications. It was utilized to further develop the disintegration pace of ineffectively water-dissolvable medications. The rate of dissolution in the gastrointestinal tract frequently controls the oral absorption rate for class drugs (class IV) and poorly soluble drugs (class II). The new "Liquisolid" innovation forms fluid medications (for example arrangements, suspensions, or emulsions of sleek fluid medications and water-insoluble strong medications moved in a non-unpredictable fluid transporter) into powders reasonable for tableting or epitome. can be applied In light of the fact that fluid tablets contain an answer of medication in a reasonable dissolvable.

The idea of "fluid strong tablet" was brought into the world from "powder disintegration

innovation" that recommends "fluid". A solid drug dispersed in a suitable non-volatile liquid carrier is referred to as a "liquid drug." Powdered excipients are created by simply combining these "liquid drugs" with the preferred carrier and coating material. These excipients have a dry appearance, are non-sticky, are highly flowable, and are well tolerated. Spireas and Bolton proposed that particles with profoundly permeable surfaces, like cellulose, starch, and lactose, could be utilized as transporter materials. As the water content of the transporter builds, the flowability of the powder diminishes. The powder cannot continue to flow without a surface coating. Consequently, the covering material ought to be an extremely fine and profoundly adsorptive silica powder.

Oral medication organization is a valid course of conveyance because of its high understanding consistence, simplicity of organization, and cost-viability.

1.1 Concept of liquisolid Technique^[5-7]

When a drug that has been dissolved in a liquid vehicle is incorporated into a carrier material with a porous surface and densely entangled fibers inside, such as cellulose, both absorption and adsorption take place. Fluid at first retained inside the molecule is caught by the inner construction of the molecule.

Adsorption of liquids occurs on the inner and outer surfaces of the porous carrier particles when this process reaches saturation. Second, covering materials with high adsorption properties and huge explicit surface regions grant positive stream properties to fluid strong frameworks. In the Liquisolid framework, the medication is now broken up in the fluid vehicle and is conveyed by the powder. The wettability of pellets in disintegration media is one of the components proposed to make sense of the expanded disintegration rate from fluid pellets.

The non-unstable dissolvable present in the Liquisolid framework works with the wetting of the medication particles by bringing down the interfacial pressure between the disintegration

medium and the tablet surface. Accordingly, fluid solids can be anticipated to display further developed discharge profiles for water-insoluble medications, as the successful surface region for wettability and disintegration is extraordinarily expanded.

1.2 Classification of Liquisolid systems: ^[8-10]

A. There are three subgroups of liquid solid systems based on the type of liquid medication they contain:

1. Powdered drug solutions
2. Powdered drug suspensions
3. Powdered liquid drugs

The conversion of can yield the first two. drug arrangements or [e. g. prednisolone arrangement in propylene glycol] or drug suspensions [e. g. gemfibrozil suspension in Polysorbate 80], and the last option from the detailing of fluid medications [e. g. clofibrate, fluid nutrients, etc.], into Liquisolid frameworks. Since non-unpredictable solvents are utilized to Prepare the liquid vehicle, the drug solution or suspension. doesn't dissipate and in this way, the medication is conveyed inside the fluid framework which thusly is scattered all through the final result.

Based on the formulation technique used, Liquisolid systems may be classified into two categories:

1. Liquisolid compacts
2. Liquisolid microsystems.

Liquisolid compacts are ready for the improvement of tablets or cases utilizing the recently depicted process, while Liquisolid microsystems depend on a cutting edge thought that utilizes comparative strategy joined with the expansion of an added substance, e.g., G., Polyvinylpyrrolidone [PVP], in the liquid drug contained within the coating and carrier materials to make an acceptably streaming admixture. The advantage coming from this new strategy is simply the coming about unit size of Liquisolid microsystems might be as much as multiple times not exactly that of Liquisolid compacts.

1.3 Main components of Liquisolid system ^[11-14]

Coating Material and Carrier Material:

Material for coating structures a uniform film around transporter particles. This forestalls molecule total and diminishes between particulate grinding. This phenomenon enhances flowability and gives the appearance of dryness. appearance to

the Liquisolid by covering the wet carrier particles and absorbing any liquid that isn't needed. Usually, the covering materials are extremely fine. Instance of covering material is colloidal silica of various grades like Aerosil 200. Furthermore, the transporter material ought to have permeable surface and firmly tangled strands in its inertial. Transporters are engaged with the fluid prescription sorption process that further develops the compelling disintegration surface region. Illustration of covering material is colloidal silica of various grades comparable to Aerosil 200.

Non-Volatile Solvent:

The chosen solvent ought to the capacity to enough disintegrate the medication. Appropriate Vehicles are inert because they can be dissolved in water and having expanded limit, similar to propylene glycol and fixed oils. The type and concentration of the formulation will be primarily based on the purpose of the observation during use of disintegrant. Converging of super-disintegrant is positive for studies to further develop solvency. Starch glycolate sodium is the most usually utilized disintegrant.

1.4 ADVANTAGES ^[15-17]

- The liquisolid compacts are truly adaptable as they are utilized for inadequately solvent medications.
- The bioavailability of oral medications which are insoluble in water is expanded.
- The expense of assembling is modest contrasted with delicate gelatin.
- The medication can be planned in numerous ways where it is available in a solubilised structure that can expand the wetting property and further develops drug discharge profile.
- Liquisolid compacts can be made from instant release or continuous release dosage forms, depending on the nature of the carriers use.
- The assembling effectiveness and the procedures can be gotten to the next level.

1.5 LIMITATION ^[18-20]

- As it is utilized exclusively for low portion water insoluble medications it can't be utilized in that frame of mind of high portion water insoluble medications.
- The heaviness of the tablet is expanded because of the expansion of transporter and covering material.
- Drug delivery can be improved by adding substances with more noteworthy retention rate

however this outcomes in a diminished tablet size.

- In the event that the adequate pressure isn't accomplished it brings about deficient hardness of the item. The drug's solubility in non-volatile liquids determines its bioavailability and dissolution rate.

1.6 Mechanisms Involved in Lquisolid Systems [21-23]

An issue of worry for some drug researchers is to upgrade the solvency and disintegration of these inadequately water-solvent medications and work on their bioavailability. The bioavailability of these Biopharmaceutical Grouping Framework class II (BCS II) drugs is




Fig 1. Schematic of the Lquisolid system.

Tablets made of lquisolids, which are safe to take orally organic solvents that dissolve in water and have a high boiling point like as propylene glycol and polyethylene glycol (Stake) 400 are utilized as the fluid vehicle. A lquisolid framework might show improved watery solvency, expanded disintegration rate, further developed wetting properties and impede drug absorption. Dissolvability upgrade and One of the biggest problems is making the drug more bioavailable. related with drug measurements structures.

many times restricted by their solvency and disintegration rate.

Lquisolid strategy was first presented by Spireas, et al. furthermore, applied to integrate water-insoluble medications into fast delivery strong measurement structures. The lquisolid method is planned so as to contain fluid drugs (drugs in the form of solutions, suspensions, or liquids) in powdered structure and conveyance drug along these lines to delicate gelatin case containing fluids.

The term "lquisolid technique" refers to the cycle that changes over fluid meds into dry, nonadherent free streaming and compressible powder combinations by mixing the fluid drugs with reasonable excipients like transporters and covering materials.

1.7 Methodology [24-25]

The required measures of the medication applicant and given measure of non-unpredictable dissolvable is gauged and afterward added, the blend is upset, exposed to warm if vital. This creates a medication arrangement and to this arrangement transporter molecule and it are added to cover materials. The most common way of blending ought to be finished in three phases design as expressed by Spireas et al

First Stage

The weighed components were mixed at a rate of one rotation per second or minute, allowing

the aqueous medication to concentrate in the powder.

Second Stage

To ensure that the liquid is completely absorbed into the powder particles' voids, the above mixture should be soaked on the surface of the mortar for approximately five minutes.

Third Stage

Blend the above combination in with super disintegrant at blending speed for 30 seconds to deliver a last combination prepared for compression.

1.8 Theory/calculation ^[26-27]

Spirease portrayed a fundamental numerical model for theme definition in a liquisolid framework.

This approach depends on the flowable (Φ -esteem) and compressible (Ψ -number) fluid maintenance potential presenting constants for each powder/fluid blend.

The maximum liquid weight that can be retained per unit weight of powder material in order to produce an acceptable liquid/powder admixture is referred to as the Φ -value. The Ψ -esteem is characterized as the most extreme load of fluid that can be held per unit weight of the powder material to deliver an acceptably compressible fluid or powder admixture for example having the option to yield tablets of agreeable mechanical strength without introducing any fluid extracting from liquisolid mass during pressure. The excipients proportion (R) or the carrier:coating material proportion is addressed as follows:

$$R = Q / q$$

where, R is ratio of carrier (Q) and coating materials (q).

R is proportion of transporter (Q) and covering materials (q). For, a fruitful definition plan, this proportion R ought to be reasonably chosen. Contingent upon the excipient proportion (R) of the powder substrate an acceptably streaming and compressible liquisolid framework can be gotten provided that a most extreme fluid burden on the transporter material isn't surpassed.

This fluid/transporter proportion is named "fluid burden factor L_f [w/w] and is characterized as the weight proportion of the fluid definition (W) and the transporter material (Q) in the framework.

$$L_f = W/Q$$

Where.

L_f = load factor

W = weight of liquid medication

Q = weight of carrier material

The ratio of the weights of the formulation's carrier (Q) and coating (q) material is represented by R . The fluid burden factor that guarantees adequate flowability (L_f) not entirely settled by:

$$L_f = \Phi + \phi (1/R)$$

Where Φ and ϕ are the Φ -upsides of the transporter and covering material, separately. Essentially, the fluid burden factor for creation of liquisolid frameworks with ok compactability (ΨL_f) not entirely set in stone by:

$$\psi L_f = \psi + \phi (1/R)$$

Where Ψ and ψ are the Ψ -numbers of the carrier and coating material.

1.9 Evaluation of Liquisolid System ^[28-29]

Flow Behaviour

Bulk density

The powder mix is gauged (W) and moved into an estimating chamber that is evaluated and the mass volume (V_b) is determined. Mass not set in stone by the equation

$$\text{Bulk density} = W/V_b$$

Tapped Density

The powder is gauged (W) and moved into a reviewed estimating chamber and tapped for a proper number of times then the tapped volume (V_t) is estimated. The tapped thickness is given as

$$\text{Tapped density} = W/V_t$$

Compressibility Index

The compressibility index is given by the following equation:

$$\text{Compressibility Index} = (\text{Tapped Density} - \text{Bulk Density}) / \text{Tapped Density} \times 100$$

Compressibility index values lower than 15 % shows good flow characteristics of powders and values higher than 25 % indicate poor flow nature.

Hausner's Ratio

It fluctuates relying upon the decision of strategy chose to decide, subsequently it isn't considered as a basic boundary. Great stream property demonstrates that the worth is beneath 1.25 and on the off chance that it is above 1.5 it shows unfortunate flowability, it is assessed as

$$\text{Hausner's ratio} = \text{tapped density} / \text{bulk density}$$

Angle of Repose

Using a funnel, it is determined by allowing the powder to flow through the funnel until its tip touches the powder pile. It tends to be composed as

$$\theta = \tan^{-1} h/r$$

Where, h = height of pile

r = radius of powder pile base

II. CONCLUSION

Liquisolid procedure is a coming technique for expanding the dissolvability and pace of disintegration accordingly expanding the bioavailability and the degree of retention of water-insoluble medications contrasted with other traditional tablets utilizing less creation expenses and straightforward fabricating process. The liquisolid method has demonstrated its reliability. what's more, savvy approach. Orodispersible plans were ready utilizing the liquisolid strategy, bringing about better ingestion, upgraded viability, and portion and recurrence decrease, therefore expanding adherence by patients.

REFERENCES

- [1]. Andrew, Grace, Josephat and Sabinus. A Review on Liquisolid: A Novel Technique for Enhancement of Solubility and Bioavailability of Poorly Water-Insoluble Drugs. Open Access Journal of Pharmaceutical Research, 2023; Vol.7(3),1-9.
- [2]. R. Santosh Kumar and Jampana Divija Sai. Liquisolid Compacts: A Review. Journal of Drug Delivery & Therapeutics. 2019; Vol.9(4-A),880-883.
- [3]. G Deepika*, Madhu Gudipati, Rama Rao Nadendla. A Comprehensive Review on Liquisolid Tablets. Int. J. Pharm. Sci. Rev. Res, 2021, Vol.67(1),195-201.
- [4]. Patil Jayesh Arun*, Deshmukh T.V. A Review: Innovational Approach to Enhanced Dissolution by Using Liquisolid Compact Technique. International journal of pharmacy & Pharmaceutical research, 2023; Vol. 26(3),141-155.
- [5]. Yaseen Hussain , Jinghao Cui, Amos Dormocara , Haroon Khan. The most recent advances in liquisolid technology: Perspectives in the pharmaceutical industry. Pharmaceutical Science Advances, 2024; Vol. 2,1-12.
- [6]. Patel UB, Modi DC, Shah DP et al. Liquisolid compacts: A review. International Journal of Advances in Pharmaceutics. 2017; 06(07): 110-113.
- [7]. Patel BB, Shah CN et al. Recent research on liquisolid technology for solubility enhancement- A review. International Journal of Advance in Pharmaceutics. 2016; 345-394.
- [8]. Balaji A, Umashankar MS, B.Kavitha B. et al. Liquisolid technology- A latest review. International Journal of Applied Pharmaceutics. 2014; 6(1): 11-9.
- [9]. Göke K, Lorenz T, Repanas A, Schneider F, Steiner D, Baumann K, et al. Novel strategies for the formulation and processing of poorly water-soluble drugs. Eur J Pharm Biopharm. 2018;126:40-56.
- [10]. Bertoni S, Hasa D, Albertini B, Perissutti B, Grassi M, Voinovich D, Passerini N. Better and greener: sustainable pharmaceutical manufacturing technologies for highly bioavailable solid dosage forms. Drug Deliv Transl Res. 2022;12(8):1843-1858.
- [11]. Ghadi R, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. J Control Release. 2017;248:71-95.
- [12]. Bhujbal SV, Mitra B, Jain U, Gong Y, Agrawal A, Karki S, et al. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. Acta Pharm Sin B. 2021;11(8):2505-2536.
- [13]. Aleksić I, Glišić T, Cvijić S, Parojčić J. Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load. Arh farm. 2022;72:61-76.
- [14]. Aleksić I, German Ilić I, Cvijić S, Parojčić J. An investigation into the influence of process parameters and formulation variables on compaction properties of liquisolid systems. AAPS PharmSciTech. 2020;21:242.
- [15]. Vranikova B, Gajdziok J, Vetchy D. Modern evaluation of liquisolid systems with varying amounts of liquid phase prepared using two different methods. Biomed Res Int. 2015;2015:608435.
- [16]. Vasiljević I, Turković E, Nenadović S, Mirković M, Zimmer A, Parojčić J, Aleksić I. Investigation into liquisolid system processability based on the SeDeM

- Expert System approach. *Int J Pharm.* 2021;605:120847.
- [17]. Pezzini BR, Beringhs AO, Ferraz HG, Silva MAS, Stulzer HK, Sonaglio D. Lquisolid technology applied to pellets: Evaluation of the feasibility and dissolution performance using felodipine as a model drug. *Chem Eng Res Des.* 2016;110:62–69.
- [18]. Vraníková B, Svačinová P, Marushka J, Brokešová J, Holas O, Tebbens JD, Šklubalová Z. The importance of the coating material type and amount in the preparation of liquisolid systems based on magnesium aluminometasilicate carrier. *Eur J Pharm Sci.* 2021;165:105952.
- [19]. Aleksić I, Vasiljević I, Glišić T, Cvijić S, Parojčić J. Lquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties. Paper presented at: 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 2021:11-14.
- [20]. Jadhav NR, Irny PV, Patil US. Solid state behavior of progesterone and its release from Neusilin US2 based liquisolid compacts. *J Drug Deliv Sci Technol.* 2017;38:97–106.
- [21]. Komala DR, Janga KY, Jukanti R, Bandary S. Competence of raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation. *J Drug Deliv Sci Technol.* 2015;30:232–241.
- [22]. Elkordy AA, Essa EA, Dhupad S, Jammigumpula P. Lquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles. *Int J Pharm.* 2012;434(1-2):122–132.
- [23]. Butania SB, Prajapata MD, Gohelb MC. Lquisolid: a promising technique to improve dissolution efficiency and bioavailability of poorly water-soluble nimodipine. *J Drug Delivery Sci Tech* 2019;53:101135.
- [24]. Kaarashima M, Ikeda Y, Sano N. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations. *Eur J Pharm Biopharm* 2017;115:65-72.
- [25]. Lee BJ, Kim D, Park C. Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjuvant for poorly water-soluble drugs via self-assembly and nanonization. *Int J Pharm* 2020;575:118892.
- [26]. Lam M, Nokhodchi A, Ghafourian T. Lquisolid system and Liqui-mass system are not same. *AAPS* 2020;21:105.
- [27]. Lam M, Nokhodchi A, Ghafourian T. Optimising the release rate of naproxen liqui-pellet: a new technology for emerging novel oral dosage form. *Drug Delivery Tran Res* 2020;10:43-58.
- [28]. Ding P, Lu M, Wang D. Lquisolid technique and its applications in pharmaceuticals. *Asian J Pharm Sci* 2017;12:115-23.
- [29]. Lam M, Nokhodchi A, Ghafourian T. Liqui-pellet: the emerging next-generation oral dosage form which stems from Lquisolid concept in combination with Pelletization technology. *AAPS* 2019;20:231.
- [30]. Li J, Wang R, Han J. Involvement of metabolism permeability in enhancing the oral bioavailability of curcumin in excipient free solid dispersions co-formed with piperine. *Int J Pharm* 2019;561:9-18.